In a nutshell This phase 2 clinical trial will test the safety and effectiveness of blinatumomab (Blincyto) after an R-chemotherapy in treating newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). The primary outcome will be measured by adverse (negative) side effects. The details Blinatumomab is an immunotherapy that uses the...
Read More
In a nutshell This phase 1/2 clinical trial will test the response to AFM13 in patients with relapsed or refractory cutaneous (on the skin) CD30 positive lymphomas. The primary outcome will be measured by immune system activity. This study will be conducted at the Center for Lymphoid Malignancies in New York, New York. The details AFM13 is an...
Read MoreIn a nutshell This phase 2 clinical trial will test the effectiveness of TGR-1202 in patients with relapsed or refractory follicular lymphoma. The primary outcome will be measured by the overall response rate. This trial is being conducted at the Columbia University Medical Center in New York, New York. The details TGR-1202 (umbralisib)...
Read MoreIn a nutshell This phase 2 clinical trial will test the effectiveness and safety of ublituximab (TG-1101) and TGR-1202 with or without bendamustine (Treanda), as well as TGR-1202 alone in treating patients with relapsed or refractory non-Hodgkin’s lymphoma. The primary outcome will be measured by the overall response. The details...
Read More
In a nutshell This phase 3 clinical trial will test the effectiveness of copanlisib (BAY 80-6946) with a standard immunochemotherapy (R-CHOP or R-B) compared to immunochemotherapy alone in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by the time to disease progression and the maximum...
Read More
In a nutshell This review outlined the current treatment options for patients with mantle cell lymphoma and highlighted possible future therapies. Some background Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma that usually affects older people and men. MCL is considered aggressive and incurable. MCL treatment is based on many...
Read More
In a nutshell This study reviews different types of hematopoietic stem cell transplantation for patients with diffuse large B-cell lymphoma and follicular lymphoma. The study concluded that autologous and allogeneic stem cell transplantation can be used to effectively treat patients with diffuse large B-cell lymphoma and follicular lymphoma in specific...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of axicabtagene ciloleucel (KTE-C19) in treating relapsed or refractory (unresponsive to treatment) indolent non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by the response rate. The details Axicabtagene ciloleucel is a chimeric antigen...
Read More
In a nutshell The authors looked at relapses that occur in the central nervous system of patients with non-Hodgkin lymphoma who were treated with EPOCH chemotherapy and rituximab. The authors concluded that there is no increased risk of CNS relapse when treated with EPOCH-R compared with previous treatments. Some background Many forms of...
Read More
In a nutshell This study looks at the outcomes for patients over 80 years old who have diffuse large B-cell lymphoma. The study concluded that patients over 80 had significantly better outcomes when treated with rituximab and anthracycline-based chemotherapy, such as the R-CHOP treatment. Some background Diffuse large B-cell lymphoma (DLBCL)...
Read More
In a nutshell This study looked at the difference in outcomes for patients with mantle cell lymphoma who were treated with either VR-CAP or R-CHOP chemotherapy regimens. The authors concluded that patients treated with VR-CAP had significantly better outcomes than patients who were treated with R-CHOP. Some background Mantle cell lymphoma (MCL) is...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of EPOCH, a 5-drug combination chemotherapy, with rituximab (Rituxan) in patients with certain types of non-Hodgkin's lymphoma. The primary outcome will be measured by the overall response and time to disease progression. This trial is being conducted in Maryland, in the...
Read More
